Statement: several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2
Primary_evidence: Adverse Events 1:   Total: 1/35 (2.86%)   congestive heart failure *1/35 (2.86%) Adverse Events 2:   Total: 0/40 (0.00%)   congestive heart failure *0/40 (0.00%)